The Therapeutic Potential of Carbon Monoxide for Inflammatory Bowel Disease | Zendy

Tomohisa Takagi | Zendy; Kazuhiko Uchiyama | Zendy; Yuji Naito | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Therapeutic Potential of Carbon Monoxide for Inflammatory Bowel Disease

Author(s) -

Tomohisa Takagi,

Kazuhiko Uchiyama,

Yuji Naito

Publication year - 2015

Publication title -

digestion

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.882

H-Index - 75

eISSN - 1421-9867

pISSN - 0012-2823

DOI - 10.1159/000368765

Subject(s) - inflammatory bowel disease , pathogenesis , ulcerative colitis , inflammation , medicine , immunology , disease , crohn's disease , colitis , inflammatory bowel diseases , pathology

Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, are chronic, relapsing and remitting inflammatory disorders of the intestinal tract. Because the precise pathogenesis of IBD remains unclear, it is important to investigate the pathogenesis of IBD and to evaluate new anti-inflammatory strategies. Recent accumulating evidence has suggested that carbon monoxide (CO) may act as an endogenous defensive gaseous molecule to reduce inflammation and tissue injury in various organ injury models, including intestinal inflammation. Furthermore, exogenous CO administration at low concentrations is protective against intestinal inflammation. These data suggest that CO may be a novel therapeutic molecule in patients with IBD. In this review, we present what is currently known regarding the therapeutic potential of CO in intestinal inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research